High urgency

Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I

Detected July 30, 2026 · in Pharmaceutical Manufacturing (FDA/DEA)

DEA places 3-Methoxyphencyclidine (3-MeO-PCP) into Schedule I, making it illegal to manufacture, distribute, or possess without DEA authorization.

Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 30, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmaceutical manufacturers, API suppliers, contract manufacturers, and compounding pharmacies (503B) that handle or intend to handle 3-Methoxyphencyclidine. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective March 23, 2026 (date of publication in the Federal Register).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

3-Methoxyphencyclidine is now classified as a Schedule I controlled substance under the Controlled Substances Act.

Who it affects

All pharmaceutical manufacturers, API suppliers, contract manufacturers, and compounding pharmacies (503B) that handle or intend to handle 3-Methoxyphencyclidine.

What you must do

Cease all manufacturing, distribution, and possession of 3-Methoxyphencyclidine unless authorized by a DEA registration for Schedule I research or other exempted activity.

Deadline

Effective March 23, 2026 (date of publication in the Federal Register).

Source: https://www.federalregister.gov/documents/2026/03/23/2026-05618/schedules-of-controlled-substances-placement-of-3-methoxyphencyclidine

Never miss a change like this again

Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmaceutical Manufacturing (FDA/DEA)